An Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Subjects With Advanced Parkinson's Disease and Severe Motor-Fluctuations Despite Optimized Treatment With Available Parkinson's Disease Medications.

Trial Profile

An Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Subjects With Advanced Parkinson's Disease and Severe Motor-Fluctuations Despite Optimized Treatment With Available Parkinson's Disease Medications.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2016

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Abbott Laboratories; AbbVie; Solvay Pharmaceuticals B.V.
  • Most Recent Events

    • 21 Apr 2016 Post-hoc subgroup analysis (n=286) of effect of levodopa-carbidopa intestinal gel on resting tremor in patients were presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 28 Jan 2016 Pooled exploratory post-hoc analysis of 3 trials including this trial and 2 other studies [see CTP 700017544 and 70033178] were published in the Movement Disorders.
    • 18 Jun 2012 Final results were presented at the 16th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top